Please try another search
Cardax, Inc. is a life sciences company. The Company develops consumer health and pharmaceutical technologies. The Company is engaged in developing and commercializing anti-inflammatory dietary supplements and drugs. The Company offers ZanthoSyn, a product to help consumers address their inflammatory health. ZanthoSyn is an astaxanthin dietary supplement distributed by the Company. ZanthoSyn features synthetic astaxanthin. Astaxanthin is an ingredient with anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health and liver health. As of December 31, 2015, the Company had two other anti-inflammatory programs with application in various markets, including zeaxanthin esters for macular degeneration and hepatic disease, and lycophyll esters for prostate disease.
Name | Age | Since | Title |
---|---|---|---|
George W. Bickerstaff | 65 | 2014 | Independent Chairman |
Makarand Jawadekar | 70 | 2018 | Independent Director |
Deepak L. Bhatt | - | 2007 | Chairman of Scientific Advisory Board |
David G. Watumull | 71 | 2014 | Chairman & CEO |
Elona Kogan | 52 | 2018 | Independent Director |
Terence A. Kelly | 59 | 2014 | Independent Director |
Michele Galen | 64 | 2017 | Independent Director |
R. Preston Mason | - | 2007 | Member of Scientific Advisory Board |
Gilbert M. Rishton | - | 2009 | Member of Scientific Advisory Board |
Paresh N. Soni | 61 | 2018 | Member of Scientific Advisory Board |
Jon L. Ruckle | - | 2013 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review